Latest news with #CML
Yahoo
a day ago
- Business
- Yahoo
With EPS Growth And More, Coronation Fund Managers (JSE:CML) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Coronation Fund Managers (JSE:CML). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Coronation Fund Managers with the means to add long-term value to shareholders. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Coronation Fund Managers managed to grow EPS by 10% per year, over three years. That's a good rate of growth, if it can be sustained. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. On the revenue front, Coronation Fund Managers has done well over the past year, growing revenue by 8.9% to R4.1b but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders. The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart. Check out our latest analysis for Coronation Fund Managers While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Coronation Fund Managers' balance sheet strength, before getting too excited. It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Coronation Fund Managers insiders have a significant amount of capital invested in the stock. We note that their impressive stake in the company is worth R1.9b. This totals to 12% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. Looking very optimistic for investors. It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. For companies with market capitalisations between R7.2b and R29b, like Coronation Fund Managers, the median CEO pay is around R19m. Coronation Fund Managers' CEO took home a total compensation package worth R13m in the year leading up to September 2024. That is actually below the median for CEO's of similarly sized companies. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of a culture of integrity, in a broader sense. One positive for Coronation Fund Managers is that it is growing EPS. That's nice to see. The fact that EPS is growing is a genuine positive for Coronation Fund Managers, but the pleasant picture gets better than that. With company insiders aligning themselves considerably with the company's success and modest CEO compensation, there's no arguments that this is a stock worth looking into. You still need to take note of risks, for example - Coronation Fund Managers has 2 warning signs we think you should be aware of. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of South African companies which have demonstrated growth backed by significant insider holdings. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
3 days ago
- Business
- Business Upturn
Alembic Pharmaceuticals shares in focus after USFDA nod for cancer drug Bosutinib
By Aditya Bhagchandani Published on May 30, 2025, 12:04 IST Shares of Alembic Pharmaceuticals may be in focus after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its generic Bosutinib Tablets in 100 mg and 500 mg strengths. Bosutinib is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or intolerant to prior therapy. According to IQVIA data, the estimated market size for Bosutinib Tablets in the US stood at USD 291 million for the twelve months ending March 2025. Alembic stated that the approved product is therapeutically equivalent to Bosulif Tablets, originally marketed by PF Prism C.V. With this latest nod, Alembic has received a cumulative total of 223 ANDA approvals from the USFDA, comprising 200 final approvals and 23 tentative approvals. This development reinforces Alembic's commitment to expanding its oncology portfolio in the US generics market. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Otago Daily Times
22-05-2025
- Automotive
- Otago Daily Times
Open days to shed light on 60 year old club
Working on a 1912 sprayer are South Canterbury Traction Engine Club members (from left) Jim Bruggeman, Malcolm Crossen (the longest-serving active member), Fred White and David Gander. PHOTO: SHELLEY INON The South Canterbury Traction Engine Club has been steaming along for 60 years. The club's original shed is now surrounded by five more, and club members are hoping to add a seventh. Club member Jeremy Talbot said one of the new additions to the museum — which members were refurbishing at present — was a 1912 sprayer from an orchard in Kurow. Mr Talbot said the dry climate had kept the sprayer "in such good nick". He said as the land was not as easy to work as Mid Canterbury, a wider range of machines could be found here. Its diverse agricultural sector, which included wheat, wool, meat and dairy, had allowed the museum to acquire a trove of vintage machines. As well as a tractor shed and truck shed, there was also a shed housing emergency vehicles from over the years. One of the fire trucks — a 1951 Commer/Merryweather TTL — was first used to fight a fire at the CML building in Stafford St in April 1951, before the vehicle had been officially commissioned. Firefighters had extended the ladder to fight the fire, but legend has it the vehicle had been left stuck overnight with its ladder extended as no-one had known how to get it down. To add insult to injury it had received a ticket for not being registered to drive on the road. Keeping the vehicles in good condition was not a cheap exercise. The club was fundraising to fix two of its engines, which both required major work. Mr Talbot said they would cost "a few bob" to fix. "We're talking thousands." He said corroded pipes were to blame for the expense. Boiler tubes had a 60-year lifespan, and as both machines were over 100 years old — and the steel came from Germany — there was no cheap fix. Once the steel arrived arrived, pulling the engines apart to replace the boiler tubes was "a bit of a job". Two open days will be held this weekend, from 10am to 4pm at the Kyle Park Transport Museum. A bouncy castle, children's rides, food and coffee will be available. A chaff cutter will be running at the open days to provide feed for horses, and pea straw will be available.
Time of India
22-05-2025
- Health
- Time of India
THIS common ingredient found in foods and supplements is linked to Blood Cancer
A concerning study reveals that taurine, a common amino acid found in food and supplements, may fuel the growth of leukemia cells. Researchers at the University of Rochester's Wilmot Cancer Institute discovered that leukemia cells readily absorb taurine, promoting glycolysis and cancer progression. Global cancer cases are predicted to rise by 35 million in 2050, which is a 77% increase from the estimated 20 million cases in 2022, according to the World Health Organization (WHO). Amid this alarming projection, new research has revealed an unsuspected driver behind one of the most aggressive forms of cancer. The study found that an amino acid, found commonly in the food we eat, and supplements we take, could cause leukemia , one of the most aggressive forms of blood cancer . A recent study by researchers at the University of Rochester's Wilmot Cancer Institute has found that taurine, which is made naturally in the body and consumed through some foods, is a key regulator of myeloid cancers such as leukemia. The study is published in the journal Nature. In the preclinical research, the scientists were able to block the growth of leukemia in mouse models and in human leukemia cell samples by using genetic tools to prevent taurine from entering cancer cells. 'We are very excited about these studies because they demonstrate that targeting uptake by myeloid leukemia cells may be a possible new avenue for treatment of these aggressive diseases,' Jeevisha Bajaj, PhD, lead researcher and an assistant professor in the Department of Biomedical Genetics and a member of Wilmot's Cancer Microenvironment research program said in a statement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo King Charles' Cancer Secret REVEALED | Royal Whisper EXPOSES Private Health Bombshell | WATCH They also found that leukemia cells drink up taurine, which promotes glycolysis (a breakdown of glucose to produce energy) to feed cancer growth. Previous researchers have never looked at the cancer-promoting role of taurine. Leukemia has several subtypes, and the survival rates vary. This study found that taurine transporter expression is essential for the growth of multiple subtypes, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS), which all originate from blood stem cells in the bone marrow. Taurine is a non-essential amino acid found naturally in the bone marrow and also in the brain, heart, and muscles. Foods such as meats, fish, and eggs also contain taurine. It is also a key ingredient in some energy drinks and protein powders, and has been used by cancer patients anecdotally. 'Dr. Bajaj's work shows that local levels of taurine in bone marrow may enhance leukemia growth, suggesting caution in use of high-dose taurine supplementation,' Jane Liesveld, MD, a Wilmot oncologist who treats leukemia patients, said. She also noted that scientists still have a lot to learn about how leukemia cells are reprogrammed and draw energy to thrive and resist treatments. 'Metabolic reprogramming is a hallmark of cancer, and we are at the very beginning of understanding metabolic effects on leukemia cells. The prior focus has been on genetic changes, but the focus is expanding to understanding how leukemia cells are able to hijack various metabolic pathways for their own survival,' she added. In conclusion, the Wilmot team states in its Nature paper: 'Since taurine is a common ingredient in energy drinks and is often provided as a supplement to mitigate the side effects of chemotherapy, our work suggests that it may be of interest to carefully consider the benefits of supplemental taurine in leukemia patients.' The researcher noted that future studies are required to investigate levels of taurine in people with leukemia. 'Our current data suggest that it would be helpful to develop stable and effective ways to block taurine from entering leukemia cells,' she said. One step to a healthier you—join Times Health+ Yoga and feel the change
Hans India
21-05-2025
- Health
- Hans India
Mangaluru Researcher Awarded PhD for Groundbreaking Study on Chronic Myeloid Leukaemia
MANGALURU: Dr. Shivani U has been awarded a Doctor of Philosophy (PhD) by NITTE (Deemed to be University) for her pioneering research on Chronic Myeloid Leukaemia (CML), a rare form of blood cancer. Her thesis, titled 'A Study to Determine the Clinical, Haematological, Cytogenetic and Molecular Profile in Chronic Myeloid Leukemia (CML) Patients,' was successfully defended on May 8, 2025. Dr. Shivani's study offers a comprehensive assessment of CML, integrating clinical data with haematological, cytogenetic, and molecular analyses—an approach that could contribute to improved diagnosis, treatment, and prognosis of the disease. Her doctoral research was conducted under the guidance of Dr. D. Prashanth Shetty, former Professor and Coordinator of the KSHEMA Centre for Genetic Services at K.S. Hegde Medical Academy. Dr. Shetty currently serves as a Professor at the Srinivas Institute of Allied Health Sciences under Srinivas University. The doctoral committee included Dr. Reshma A. Shetty (Assistant Professor, KSHEMA Centre for Genetic Services), Dr. Vijith Shetty (Professor, Department of Oncology), and Dr. Suchetha Kumari N. (Professor, Department of Biochemistry, KSHEMA), who evaluated and supported the research work. A native of Mangaluru, Dr. Shivani is an alumna of local institutions and is known for her academic diligence. She is the daughter of Bhanukala Uday, student section head at KMC Mangalore, and Uday Kumar, formerly on staff at KMC Attavar. She will receive her doctoral degree at NITTE University's forthcoming convocation. (eom) [9:11 PM, 5/21/2025] +91 94483 00454: ಕಳಸ ಬಸದಿ ಪಂಚ ಕಲ್ಯಾಣ ಪ್ರತಿಷ್ಠಾ ಮಹೋತ್ಸವ ತಾ 18.5.2025 ರಿಂದ ತಾ. 22.5.2025 ರ ವರೆಗೆ. [9:11 PM, 5/21/2025] +91 94483 00454: KALASA, Chikkamagaluru District, Karnataka: A historic Jain temple dedicated to Sri Chandranath Tirthankara, Sri Jwalamalini Devi, Sri Parshwanath Tirthankara, and Sri Padmavati Devi has been meticulously restored in Kalasa. Reconstructed entirely in granite as per Agama traditions, the temple recently witnessed the sacred Panchakalyana Mahotsava. The ceremony was graced by Munishri Gunabhadra Maharaj and his sangha, with spiritual guidance and blessings from Karkala Seer Lalitakeerthi Bhattaraka. Bhattarakas from Hombuja, Sonda, and Shravanabelagola also participated. Philanthropist Dr. D. Veerendra Heggade visited the site for darshana. The renovation was made possible through the collective efforts of local devotees, breathing new life into an ancient spiritual landmark.
